{"id":34121,"date":"2025-05-26T14:34:32","date_gmt":"2025-05-26T06:34:32","guid":{"rendered":"https:\/\/flcube.com\/?p=34121"},"modified":"2025-05-26T14:34:33","modified_gmt":"2025-05-26T06:34:33","slug":"zhejiang-huahai-gains-medsafe-and-hdec-approval-for-hb0043-phase-i-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=34121","title":{"rendered":"Zhejiang Huahai Gains MEDSAFE and HDEC Approval for HB0043 Phase I Trial"},"content":{"rendered":"\n<p>China-based Zhejiang Huahai Pharmaceutical Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/600521:SHA\">SHA: 600521<\/a>) announced that it has received approval from the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) and the Health and Disability Ethics Committee (HDEC) to conduct a Phase I clinical study for its HB0043. This bispecific antibody (BsAb) targets interleukin-17A (IL-17A) and interleukin-36 receptor (IL-36R) and is being developed for the treatment of autoimmune diseases.<\/p>\n\n\n\n<p><strong>HB0043 Mechanism and Potential<\/strong><br>HB0043 is designed with high binding and blocking activity, enabling it to effectively inhibit cytokine-induced inflammation and fibrosis. Preclinical studies in animal models of atopic dermatitis (AD), idiopathic pulmonary fibrosis (IPF), diabetes nephropathy (DN), neutrophil asthma, and other diseases have demonstrated superior efficacy compared to single-target drugs.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/600521_20250524_VMO7.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600521_20250524_VMO7.\"><\/object><a id=\"wp-block-file--media-ee8871df-bf61-4326-96bd-24537afe8588\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/600521_20250524_VMO7.pdf\">600521_20250524_VMO7<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/600521_20250524_VMO7.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-ee8871df-bf61-4326-96bd-24537afe8588\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that it has received approval from&#8230;<\/p>\n","protected":false},"author":1,"featured_media":34124,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,775,28,1381],"class_list":["post-34121","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-huahai-pharmaceutical","tag-multi-specific-antibodies","tag-sha-600521"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Zhejiang Huahai Gains MEDSAFE and HDEC Approval for HB0043 Phase I Trial - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that it has received approval from the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) and the Health and Disability Ethics Committee (HDEC) to conduct a Phase I clinical study for its HB0043. This bispecific antibody (BsAb) targets interleukin-17A (IL-17A) and interleukin-36 receptor (IL-36R) and is being developed for the treatment of autoimmune diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=34121\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zhejiang Huahai Gains MEDSAFE and HDEC Approval for HB0043 Phase I Trial\" \/>\n<meta property=\"og:description\" content=\"China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that it has received approval from the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) and the Health and Disability Ethics Committee (HDEC) to conduct a Phase I clinical study for its HB0043. This bispecific antibody (BsAb) targets interleukin-17A (IL-17A) and interleukin-36 receptor (IL-36R) and is being developed for the treatment of autoimmune diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=34121\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-26T06:34:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-26T06:34:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2609.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34121#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34121\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zhejiang Huahai Gains MEDSAFE and HDEC Approval for HB0043 Phase I Trial\",\"datePublished\":\"2025-05-26T06:34:32+00:00\",\"dateModified\":\"2025-05-26T06:34:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34121\"},\"wordCount\":135,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34121#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2609.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Huahai Pharmaceutical\",\"Multi-specific antibodies\",\"SHA: 600521\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34121#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34121\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=34121\",\"name\":\"Zhejiang Huahai Gains MEDSAFE and HDEC Approval for HB0043 Phase I Trial - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34121#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34121#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2609.webp\",\"datePublished\":\"2025-05-26T06:34:32+00:00\",\"dateModified\":\"2025-05-26T06:34:33+00:00\",\"description\":\"China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that it has received approval from the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) and the Health and Disability Ethics Committee (HDEC) to conduct a Phase I clinical study for its HB0043. This bispecific antibody (BsAb) targets interleukin-17A (IL-17A) and interleukin-36 receptor (IL-36R) and is being developed for the treatment of autoimmune diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34121#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34121\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34121#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2609.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2609.webp\",\"width\":1080,\"height\":608,\"caption\":\"Zhejiang Huahai Gains MEDSAFE and HDEC Approval for HB0043 Phase I Trial\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34121#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zhejiang Huahai Gains MEDSAFE and HDEC Approval for HB0043 Phase I Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zhejiang Huahai Gains MEDSAFE and HDEC Approval for HB0043 Phase I Trial - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that it has received approval from the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) and the Health and Disability Ethics Committee (HDEC) to conduct a Phase I clinical study for its HB0043. This bispecific antibody (BsAb) targets interleukin-17A (IL-17A) and interleukin-36 receptor (IL-36R) and is being developed for the treatment of autoimmune diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=34121","og_locale":"en_US","og_type":"article","og_title":"Zhejiang Huahai Gains MEDSAFE and HDEC Approval for HB0043 Phase I Trial","og_description":"China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that it has received approval from the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) and the Health and Disability Ethics Committee (HDEC) to conduct a Phase I clinical study for its HB0043. This bispecific antibody (BsAb) targets interleukin-17A (IL-17A) and interleukin-36 receptor (IL-36R) and is being developed for the treatment of autoimmune diseases.","og_url":"https:\/\/flcube.com\/?p=34121","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-26T06:34:32+00:00","article_modified_time":"2025-05-26T06:34:33+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2609.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=34121#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=34121"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zhejiang Huahai Gains MEDSAFE and HDEC Approval for HB0043 Phase I Trial","datePublished":"2025-05-26T06:34:32+00:00","dateModified":"2025-05-26T06:34:33+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=34121"},"wordCount":135,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=34121#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2609.webp","keywords":["Clinical trial approval \/ initiation","Huahai Pharmaceutical","Multi-specific antibodies","SHA: 600521"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=34121#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=34121","url":"https:\/\/flcube.com\/?p=34121","name":"Zhejiang Huahai Gains MEDSAFE and HDEC Approval for HB0043 Phase I Trial - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=34121#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=34121#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2609.webp","datePublished":"2025-05-26T06:34:32+00:00","dateModified":"2025-05-26T06:34:33+00:00","description":"China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that it has received approval from the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) and the Health and Disability Ethics Committee (HDEC) to conduct a Phase I clinical study for its HB0043. This bispecific antibody (BsAb) targets interleukin-17A (IL-17A) and interleukin-36 receptor (IL-36R) and is being developed for the treatment of autoimmune diseases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=34121#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=34121"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=34121#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2609.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2609.webp","width":1080,"height":608,"caption":"Zhejiang Huahai Gains MEDSAFE and HDEC Approval for HB0043 Phase I Trial"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=34121#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zhejiang Huahai Gains MEDSAFE and HDEC Approval for HB0043 Phase I Trial"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2609.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34121","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34121"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34121\/revisions"}],"predecessor-version":[{"id":34125,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34121\/revisions\/34125"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/34124"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34121"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34121"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34121"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}